Identifying FDA-Approved Drugs with Multimodal Properties against COVID-19 Using a Data-Driven Approach and a Lung Organoid Model of SARS-CoV-2 Entry

Researchers used a data-driven approach, combining results from the screening of a large transcriptomic database and molecular docking analyses, with in vitro tests using a lung organoid model of SARS-CoV-2 entry, to identify drugs with putative multimodal properties against COVID-19.